Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease. 

Biotechnology

Atsena Therapeutics

Patrick Ritschel

Mallory Bissett, MBA

Melissa M Endejann

Kevin Mouillesseaux

Rachel Smith

Michael Kelly

Sanford Boye

Kenji Fujita

The Research and Development team at Atsena Therapeutics is dedicated to advancing cutting-edge gene therapies aimed at reversing or preventing blindness. This team, composed of experts in translational research and assay development, collaborates to innovate and refine AAV-based therapies. By focusing on both clinical trials and preclinical assets, the team strives to address critical challenges in inherited retinal diseases and bring transformative treatments to patients in need.

Research and Development

Clinical Operations Team

Leadership Team

Research and Development

About

Team members

Other teams at Atsena Therapeutics

Clinical Operations Team

Leadership Team